MSLE — Satellos Bioscience Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1421642 ·
Ontario, Canada
Last close
$6.20
Market Cap
$131.54M
52W High
$13.40
52W Low
$5.44
ADV30
51,718
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -11,677,000 | -11,168,000 | 57,985,000 | 6,175,000 | 8,362,000 |
| Jun 2026 | 0 | — | -12,165,000 | -11,718,000 | 65,769,000 | 7,393,000 | 5,861,000 |
| Mar 2026 | 0 | — | -10,043,000 | -9,768,000 | 75,226,000 | 18,697,000 | 4,563,000 |
| Dec 2025 | 0 | — | -7,647,000 | -7,303,000 | 31,889,000 | 9,804,000 | 4,105,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,000,000
Investing CF
$-54,566,000
Financing CF
$52,785,000
CapEx
$-7,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.84
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-103,456,000
Inventory
—
Receivables
$783,000
ST Investments
$54,446,000
EBIT TTM
$-35,821,000
Pretax Income TTM
$-34,456,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,459,000 | -24,873,000 | 31,889,000 | 4,105,000 | 27,784,000 | -23,596,000 |
| Dec 2024 | 0 | -20,398,000 | -20,634,000 | 50,747,000 | 3,583,000 | 47,164,000 | -18,252,000 |
| Dec 2023 | 0 | -11,656,113 | -11,977,235 | 33,490,000 | 2,734,000 | 30,756,000 | -8,732,851 |
| Dec 2022 | 0 | -6,209,844 | -8,342,175 | 4,567,492 | 2,085,175 | 2,482,317 | -4,260,978 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.73
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MGNX | MACROGENICS INC | $131.01M | $2.05 | — |
| MENS | Jyong Biotech Ltd. | $133.62M | $1.80 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $124.92M | $4.33 | — |
| SION | Sionna Therapeutics, Inc. | $138.87M | $3.07 | — |
| ALXO | ALX ONCOLOGY HOLDINGS INC | $138.97M | $1.00 | — |
News headlines (Yahoo Finance, 1h cache)
Satellos Bioscience's Phase 2 Data Readout Could Drive Significant Upside, Oppenheimer Says
2026-11-13 16:48 · Yahoo
Satellos Bioscience: Q3 Earnings Snapshot
2026-11-12 12:13 · Yahoo
Satellos Reports Third Quarter 2026 Financial Results and Highlights Company Progress
2026-11-12 12:00 · Yahoo
Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results
2026-11-07 02:14 · Yahoo
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
2026-11-06 12:00 · Yahoo
Satellos to Host Investor Call to Provide an Update on Clinical and Regulatory Strategy for the BASECAMP Phase 2 Pediatric Study
2026-11-05 21:32 · Yahoo
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
2026-10-27 11:00 · Yahoo
Satellos to Participate in Upcoming Investor Conferences
2026-10-21 11:00 · Yahoo
Satellos Bioscience Completes Enrollment in Phase 2 Basecamp Trial
2026-09-30 18:00 · Yahoo
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
2026-09-30 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.